- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
West Chester Today
By the People, for the People
Verrica Pharmaceuticals to Present at Annual Healthcare Conference
The company will showcase its dermatology drug pipeline at the 25th Annual Needham Virtual Healthcare Conference.
Apr. 6, 2026 at 1:42pm
Got story updates? Submit your updates here. ›
Verrica Pharmaceuticals, a therapeutics company developing medications for dermatological diseases, announced that its President and CEO Jayson Rieger will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company's lead product, YCANTH® (VP-102), is the first FDA-approved treatment for molluscum contagiosum, a common viral skin infection, and is also in development to treat common warts.
Why it matters
Verrica's participation in this high-profile healthcare investment conference signals the company's progress in advancing its dermatology drug pipeline, which includes treatments for common skin conditions that currently lack effective therapies. The presentation will provide investors and the broader industry insights into Verrica's commercial strategy and R&D initiatives.
The details
Verrica Pharmaceuticals, a West Chester, Pennsylvania-based therapeutics company, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET. The presentation will be delivered by Jayson Rieger, PhD, MBA, the company's President and Chief Executive Officer. Verrica's lead product, YCANTH® (VP-102), is the first and only healthcare professional-administered treatment approved by the FDA to treat molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the U.S., primarily children. YCANTH® is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Additionally, Verrica has licensed VP-315 (ruxotemitide) from Lytix Biopharma AS to develop and commercialize the drug for non-melanoma skin cancers.
- The 25th Annual Needham Virtual Healthcare Conference will take place from April 13-16, 2026.
- Verrica's presentation is scheduled for Wednesday, April 15, 2026 at 3:00pm ET.
The players
Verrica Pharmaceuticals Inc.
A therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers.
Jayson Rieger, PhD, MBA
The President and Chief Executive Officer of Verrica Pharmaceuticals.
YCANTH® (VP-102)
Verrica's lead product, the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum, a highly contagious viral skin infection.
VP-315 (ruxotemitide)
A drug licensed by Verrica from Lytix Biopharma AS to develop and commercialize for non-melanoma skin cancers.
What’s next
Investors and the public will be able to access a live webcast of Verrica's presentation at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. A replay of the webcast will also be available for 90 days following the event.
The takeaway
Verrica Pharmaceuticals is making strides in developing innovative dermatology treatments, including the first FDA-approved therapy for molluscum contagiosum, a common and highly contagious viral skin infection. The company's participation in the prestigious Needham Healthcare Conference underscores its progress and the potential of its drug pipeline to address unmet needs in medical dermatology.
